HCW Biologics Inc.
Extracted from this filing and checked against the source text.
HCW Biologics Inc. shareholders approved Election of two Class II directors, each to serve for a three-year term expiring at the 2026 Annual Meeting of Stockholders at the 2023-06-13 meeting.
The Company’s stockholders approved the election of two Class II directors, each to serve for a three-year term expiring at the 2026 Annual Meeting of Stockholders or until such director's successor is duly elected and qualified or until such director's earlier death, resignation, disqualification or removal: Nominee For Withheld Broker Non-Votes Lisa M. Giles 18,867,295 503,344 2,228,627 Rick S. Greene 18,857,446 513,193 2,228,627View on SEC.gov
HCW Biologics Inc. shareholders approved Ratification of the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-13 meeting.
The Company’s stockholders ratified the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023: For Against Abstain Broker Non-Votes 21,550,829 3,374 45,063 N/AView on SEC.gov
560 shareholder votes filed in the last 30 days. Browse all shareholder votes →
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.